Country for PR: United States
Contributor: PR Newswire New York
Friday, February 17 2017 - 07:00
Cantel Medical to Expand Direct Sales Operations in Australia
LITTLE FALLS, New Jersey, Feb. 17, 2017 /PRNewswire-AsiaNet/ --

    - Company to acquire its Medivators(R)-branded procedural products and 
              endoscope reprocessing business from CR Kennedy
CANTEL MEDICAL CORP. (NYSE:CMD), a leading global company dedicated to 
delivering innovative infection prevention products, services and solutions, 
announced today that it entered into a definitive agreement to purchase its 
endoscopy business assets from Australian distributor, CR Kennedy & Company Pty 
Ltd. The endoscopy business assets consist of Cantel's Medivators(R)-branded 
automated endoscope reprocessors, chemistries, procedure room products and 
other consumables as well as a full sales and service organization.

Jorgen B. Hansen, President and CEO of Cantel Medical said, "This acquisition 
is in line with Cantel's strategy to expand its products and services into key 
markets to provide global solutions that meet local needs. It also accelerates 
our ability to offer customers in Australia an expanded Medivators(R)-branded 
product portfolio while maintaining the high-quality service and support that 
our customers expect."

"The expansion of our commercial platform and the addition of a direct sales 
and service organization for our Endoscopy business provides Cantel with near- 
and long-term growth opportunities. It also broadens our leadership and 
strengthens our share in the infection prevention market in Australia," stated 
David Rosen, President, Continental Europe, Middle East and Asia-Pacific. "We 
would like to thank CR Kennedy for the many years of outstanding support of the 
Medivators(R) business in Australia and for their partnership and role in 
helping us achieve this milestone."

Subject to customary closing conditions, Cantel expects the transaction to 
close on or around April 1, 2017.

About Cantel Medical

Cantel Medical is a leading global company dedicated to delivering innovative 
infection prevention products and services for patients, caregivers, and other 
healthcare providers which improve outcomes, enhance safety and help save 
lives.  Our products include specialized medical device reprocessing systems 
for endoscopy and renal dialysis, advanced water purification equipment, 
sterilants, disinfectants and cleaners, sterility assurance monitoring products 
for hospitals and dental clinics, disposable infection control products 
primarily for dental and GI endoscopy markets, dialysate concentrates, hollow 
fiber membrane filtration and separation products. Additionally, we provide 
technical service for our products.  For further information, visit the Cantel 
website at

This press release contains forward-looking statements within the meaning of 
the Private Securities Litigation Reform Act of 1995. These statements involve 
a number of risks and uncertainties, including, without limitation, the risks 
detailed in Cantel's filings and reports with the Securities and Exchange 
Commission. Such forward-looking statements are only predictions, and actual 
events or results may differ materially from those projected or anticipated.

SOURCE  Cantel Medical Corp.

CONTACT: Milicent Brooks, Corporate Communications, Cantel Medical Corp., 
Phone: +1 (973) 774-7452; Richard E. Moyer, Cameron Associates, Inc.,, Phone: +1 (212) 554-5466